ProKidney Corp. (BMV:PROK)

Mexico flag Mexico · Delayed Price · Currency is MXN
38.20
-1.25 (-3.17%)
At close: Jan 20, 2026
17.32%
Market Cap5.33B
Revenue (ttm)13.65M
Net Income (ttm)-1.30B
Shares Outn/a
EPS (ttm)-9.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume15,600
Average Volume20,712
Open38.26
Previous Close39.45
Day's Range38.20 - 38.26
52-Week Range12.18 - 132.00
Betan/a
RSI41.81
Earnings DateMar 18, 2026

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 204
Stock Exchange Mexican Stock Exchange
Ticker Symbol PROK
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements